Urovant Sciences Ltd (UROV)

[Grant Lee]

Finally, Sumitomo, a japanese company, owns 75% of the outstanding shares. Urovant does not need seasoned equity offerings to raise capital because Sumitomo has offered debt financing, preventing dilution. It is most likely Urovant will eventually be bought out fully by Sumitomo as Urovant finishes building out its commercial and market access infrastructure. Sumitomo will benefit from allowing Urovant to build out its own team because of the large equity ownership by the management team. This has allowed for a state of the art team to be constructed, which benefits Sumitomo, which has no United States infrastructure to launch Vibegron.